On August 21, 2026, Hang Seng Indexes Company unveiled the results of its quarterly index review as of June 30, 2026, with IMPACT THERAP-B (07630) being added to the Hang Seng Composite Index. The adjustment will take effect after the market close on Friday, September 4, and become active from Monday, September 7, at which point the Shanghai and Shenzhen stock exchanges will correspondingly update the eligible securities list for Stock Connect trading.

IMPACT THERAP-B is now positioned for potential inclusion in the Stock Connect program, having met a comprehensive set of criteria covering market capitalization, liquidity, and other key metrics. The stock surged over 10% during the trading session, closing at HK$13.46.

On August 12, the company announced the nomination of IMP2794 as a preclinical candidate compound (PCC), which is a KAT6A-specific degrading PROTAC. This marks the first PCC to emerge from the company's proprietary targeted protein degradation platform, which encompasses proteolysis-targeting chimeras (PROTACs), validating the technical maturity and output capability of the platform.

The company has established a degradation platform built on an E3 ligase library and linker library, enabling rapid assembly of PROTAC molecules with excellent oral bioavailability. These tools allow for selective and controllable degradation of previously "undruggable" targets, broadening the therapeutic window while reducing toxicity. The platform's mechanism complements the company's ADC platform, supporting multidimensional exploration of cancer targets.